{"disease":{"id":"seizures","name":"seizures"},"drugs":{"marketed":[{"drug_id":"perampanel","indication_name":"Secondarily generalized seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fycompa","generic_name":"PERAMPANEL","company_name":"Catalyst Pharms","drug_phase":"marketed","molecular_target":"Glutamate receptor ionotropic AMPA","drug_class":"Noncompetitive AMPA Glutamate Receptor Antagonist [EPC]","quality_score":75,"revenue":"300","mechanism":"Fycompa works by blocking the AMPA glutamate receptor, which is involved in the transmission of nerve impulses."},{"drug_id":"carbamazepine","indication_name":"Generalized Tonic-Clonic Seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tegretol","generic_name":"carbamazepine","company_name":"Novartis AG (originally Geigy)","drug_phase":"marketed","molecular_target":"Frizzled-8, Nuclear receptor subfamily 1 group I member 2, Neuronal acetylcholine receptor; alpha2/beta4","drug_class":"Mood Stabilizer [EPC]","quality_score":62,"revenue":null,"mechanism":"Carbamazepine reduces polysynaptic responses and blocks post-tetanic potentiation, potentially alleviating seizures and pain."},{"drug_id":"tiagabine","indication_name":"Partial seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gabitril","generic_name":"TIAGABINE","company_name":"Cephalon","drug_phase":"marketed","molecular_target":"Sodium- and chloride-dependent GABA transporter 1","drug_class":"Anti-epileptic Agent","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"valproate","indication_name":"Complex Partial Seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Valproate","company_name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":48,"revenue":null,"mechanism":"Valproate may increase brain GABA levels to exert its anti-epileptic effects."},{"drug_id":"valproate","indication_name":"Simple and Complex Absence Seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Valproate","company_name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":48,"revenue":null,"mechanism":"Valproate may increase brain GABA levels to exert its anti-epileptic effects."},{"drug_id":"valproate","indication_name":"Multiple Seizure Types Including Absence Seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Valproate","company_name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":48,"revenue":null,"mechanism":"Valproate may increase brain GABA levels to exert its anti-epileptic effects."},{"drug_id":"lyrica","indication_name":"Adjunctive therapy for partial-onset seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lyrica","generic_name":"Pregabalin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"alpha-2-delta subunit (auxiliary subunit of voltage-gated calcium channels)","drug_class":"Anticonvulsant, analgesic","quality_score":10,"revenue":null,"mechanism":"Pregabalin binds alpha-2-delta subunit of voltage-gated calcium channels in CNS."},{"drug_id":"rufinamide","indication_name":"Seizures associated with Lennox-Gastaut Syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Banzel","generic_name":"RUFINAMIDE","company_name":"Eisai","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 5A, mitochondrial","drug_class":"rufinamide","quality_score":10,"revenue":null,"mechanism":"Banzel works by stabilizing inactivated sodium channels in the brain, reducing the frequency of seizures."},{"drug_id":"clonazepam","indication_name":"Akinetic Seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Klonopin","generic_name":"clonazepam","company_name":"Generic (originally Roche)","drug_phase":"marketed","molecular_target":"GABA-A receptor alpha-1/beta-2/gamma-2, GABA-A receptor; anion channel, GABA-A receptor; anion channel","drug_class":"Benzodiazepine [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"clonazepam","indication_name":"Myoclonic Seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Klonopin","generic_name":"clonazepam","company_name":"Generic (originally Roche)","drug_phase":"marketed","molecular_target":"GABA-A receptor alpha-1/beta-2/gamma-2, GABA-A receptor; anion channel, GABA-A receptor; anion channel","drug_class":"Benzodiazepine [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"clonazepam","indication_name":"Absence Seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Klonopin","generic_name":"clonazepam","company_name":"Generic (originally Roche)","drug_phase":"marketed","molecular_target":"GABA-A receptor alpha-1/beta-2/gamma-2, GABA-A receptor; anion channel, GABA-A receptor; anion channel","drug_class":"Benzodiazepine [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"gabapentin","indication_name":"Partial Onset Seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neurontin","generic_name":"gabapentin","company_name":"Generic (originally Parke-Davis/Pfizer)","drug_phase":"marketed","molecular_target":"Large neutral amino acids transporter small subunit 1, Adenosine receptor A1, Alpha-2A adrenergic receptor","drug_class":"Gabapentinoid (anticonvulsant/neuropathic pain agent)","quality_score":10,"revenue":null,"mechanism":"Binds the alpha-2-delta subunit of voltage-gated calcium channels, modulating neurotransmitter release to treat neuropathic pain and seizures."},{"drug_id":"valproate-sodium","indication_name":"Complex Partial Seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"VALPROATE SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Valproate may increase brain GABA levels to exert its antiepileptic effects."},{"drug_id":"valproate-sodium","indication_name":"Simple and Complex Absence Seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"VALPROATE SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Valproate may increase brain GABA levels to exert its antiepileptic effects."},{"drug_id":"valproate-sodium","indication_name":"Multiple Seizure Types Including Absence Seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"VALPROATE SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Valproate may increase brain GABA levels to exert its antiepileptic effects."},{"drug_id":"fosphenytoin","indication_name":"Seizures During Neurosurgery","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cerebyx","generic_name":"FOSPHENYTOIN","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Sodium channel protein type 5 subunit alpha","drug_class":"Anti-epileptic Agent","quality_score":80,"revenue":null,"mechanism":"Cerebyx works by stabilizing the inactivated state of sodium channels, preventing the rapid firing of neurons that can lead to seizures."},{"drug_id":"fludeoxyglucose-f-18","indication_name":"Neurology - Epileptic Seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"FLUDEOXYGLUCOSE F 18","company_name":"","drug_phase":"marketed","molecular_target":"glucose transporter proteins, hexokinase, glucose-6-phosphatase","drug_class":"Radioactive Diagnostic Agent [EPC]","quality_score":40,"revenue":null,"mechanism":"Fludeoxyglucose F-18 is a glucose analog that accumulates in cells with high glucose metabolism, reflecting metabolic activity."},{"drug_id":"keppra","indication_name":"Epilepsy characterized by intractable complex partial seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Keppra","company_name":"Masonic Cancer Center, University of Minnesota","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 1, Sodium channel protein type 1 subunit alpha, Synaptic vesicle glycoprotein 2A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"xcopri","indication_name":"Epilepsy having focal-onset seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xcopri","company_name":"SK Life Science, Inc.","drug_phase":"marketed","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-4, Gamma-aminobutyric acid receptor subunit alpha-6","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"lyrica","indication_name":"Adjunctive therapy for partial-onset seizures in patients 1 month of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lyrica","generic_name":"Pregabalin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"alpha-2-delta subunit (auxiliary subunit of voltage-gated calcium channels)","drug_class":"Anticonvulsant, analgesic","quality_score":10,"revenue":null,"mechanism":"Pregabalin binds alpha-2-delta subunit of voltage-gated calcium channels in CNS."},{"drug_id":"fludeoxyglucose","indication_name":"epileptic seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fludeoxyglucose F-18","generic_name":"FLUDEOXYGLUCOSE","company_name":"Downstate Clincl","drug_phase":"marketed","molecular_target":"","drug_class":"Radioactive Diagnostic Agent [EPC]","quality_score":44,"revenue":null,"mechanism":"Fludeoxyglucose F-18 is a radioactive sugar molecule that accumulates in cells with high metabolic activity, allowing for visualization of cancer and other conditions."},{"drug_id":"eslicarbazepine","indication_name":"partial-onset seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Eslicarbazepine Acetate","generic_name":"ESLICARBAZEPINE","company_name":"Sumitomo Pharma Am","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":49,"revenue":null,"mechanism":"Eslicarbazepine acetate works by stabilizing sodium channels in the brain, reducing the abnormal electrical activity that causes seizures."},{"drug_id":"f-18","indication_name":"epileptic seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fludeoxyglucose F-18","generic_name":"F-18","company_name":"3D Imaging Drug","drug_phase":"marketed","molecular_target":"","drug_class":"Radioactive Diagnostic Agent [EPC]","quality_score":44,"revenue":null,"mechanism":"Fludeoxyglucose F-18 is a radioactive molecule that accumulates in areas of high metabolic activity, allowing for imaging of various conditions."},{"drug_id":"topiramate","indication_name":"Epilepsy characterized by intractable complex partial seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Topamax","generic_name":"topiramate","company_name":"Janssen","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 1 group I member 2, Carbonic anhydrase 1, Carbonic anhydrase 12","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"sodium valproate","indication_name":"Epilepsy characterized by intractable complex partial seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Epilim","generic_name":"sodium valproate","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Alcohol dehydrogenase [NADP(+)], Histone deacetylase 1, Histone deacetylase 2","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"tiagabine","indication_name":"Epilepsy characterized by intractable complex partial seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gabitril","generic_name":"TIAGABINE","company_name":"Cephalon","drug_phase":"marketed","molecular_target":"Sodium- and chloride-dependent GABA transporter 1","drug_class":"Anti-epileptic Agent","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"phenytoin","indication_name":"Epilepsy characterized by intractable complex partial seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Phenytoin Sodium","generic_name":"PHENYTOIN","company_name":"Viatris","drug_phase":"marketed","molecular_target":"Sodium channel protein type 2 subunit alpha","drug_class":"Anti-epileptic Agent","quality_score":70,"revenue":null,"mechanism":"Phenytoin Sodium works by stabilizing the threshold against hyperexcitability caused by excessive stimulation."},{"drug_id":"phenytoin","indication_name":"Prevention of Seizures following Cranial Trauma or Surgery","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Phenytoin Sodium","generic_name":"PHENYTOIN","company_name":"Viatris","drug_phase":"marketed","molecular_target":"Sodium channel protein type 2 subunit alpha","drug_class":"Anti-epileptic Agent","quality_score":70,"revenue":null,"mechanism":"Phenytoin Sodium works by stabilizing the threshold against hyperexcitability caused by excessive stimulation."},{"drug_id":"phenytoin","indication_name":"Seizures in Neurosurgery","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Phenytoin Sodium","generic_name":"PHENYTOIN","company_name":"Viatris","drug_phase":"marketed","molecular_target":"Sodium channel protein type 2 subunit alpha","drug_class":"Anti-epileptic Agent","quality_score":70,"revenue":null,"mechanism":"Phenytoin Sodium works by stabilizing the threshold against hyperexcitability caused by excessive stimulation."},{"drug_id":"ganaxolone","indication_name":"Seizures associated with CDKL5 deficiency disorders","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ztalmy","generic_name":"GANAXOLONE","company_name":"Marinus","drug_phase":"marketed","molecular_target":"GABA A receptor alpha-2/beta-1/gamma-2","drug_class":"Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator [EPC]","quality_score":48,"revenue":null,"mechanism":"Ztalmy works by enhancing the activity of the GABA A receptor, a key player in regulating the activity of neurons in the brain."},{"drug_id":"bat","indication_name":"Treatment of partial-onset seizures with and without secondary generalization in patients 12 years of age and older with epilepsy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of primary generalized tonic-clonic seizures in patients 2 years of age and older with epilepsy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of seizures associated with Lennox-Gastaut syndrome in patients 2 years of age and older with epilepsy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"carbamazepine","indication_name":"Epilepsy characterized by intractable complex partial seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tegretol","generic_name":"carbamazepine","company_name":"Novartis AG (originally Geigy)","drug_phase":"marketed","molecular_target":"Frizzled-8, Nuclear receptor subfamily 1 group I member 2, Neuronal acetylcholine receptor; alpha2/beta4","drug_class":"Mood Stabilizer [EPC]","quality_score":62,"revenue":null,"mechanism":"Carbamazepine reduces polysynaptic responses and blocks post-tetanic potentiation, potentially alleviating seizures and pain."},{"drug_id":"lamotrigine","indication_name":"Epilepsy characterized by intractable complex partial seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lamictal","generic_name":"lamotrigine","company_name":"GSK","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 3A, Sigma non-opioid intracellular receptor 1, Sodium channel protein type 1 subunit alpha","drug_class":"Anti-epileptic Agent [EPC]","quality_score":55,"revenue":null,"mechanism":null},{"drug_id":"cenobamate","indication_name":"Epilepsy having focal-onset seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xcopri","generic_name":"CENOBAMATE","company_name":"Sk Life","drug_phase":"marketed","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-4","drug_class":"","quality_score":51,"revenue":null,"mechanism":"Xcopri works by enhancing the activity of a neurotransmitter called GABA, which helps calm down abnormal electrical activity in the brain."},{"drug_id":"levetiracetam","indication_name":"Epilepsy characterized by intractable complex partial seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Keppra","generic_name":"levetiracetam","company_name":"Generic (originally UCB Pharma)","drug_phase":"marketed","molecular_target":"Synaptic vesicle protein SV2A","drug_class":"Antiepileptic agent","quality_score":10,"revenue":null,"mechanism":"Levetiracetam binds to synaptic vesicle protein SV2A, potentially regulating vesicle exocytosis."},{"drug_id":"carbamazepin","indication_name":"Epilepsy characterized by intractable complex partial seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Carbamazepin","company_name":"Enanta Pharmaceuticals, Inc","drug_phase":"marketed","molecular_target":"Frizzled-8, Nuclear receptor subfamily 1 group I member 2, Neuronal acetylcholine receptor; alpha2/beta4","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"valproic-acid","indication_name":"Epilepsy characterized by intractable complex partial seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Depakene","generic_name":"valproic acid","company_name":"Generic (originally Abbott/AbbVie)","drug_phase":"marketed","molecular_target":"Alcohol dehydrogenase [NADP(+)], Histone deacetylase 1, Histone deacetylase 2","drug_class":"Anti-epileptic Agent [EPC]","quality_score":10,"revenue":null,"mechanism":"Broad-spectrum anticonvulsant that enhances GABA activity, blocks sodium and calcium channels, and inhibits histone deacetylase."},{"drug_id":"phenobarbitone","indication_name":"Epilepsy characterized by intractable complex partial seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"phenobarbitone","company_name":"Institute of Child Health","drug_phase":"phase_1","molecular_target":"Nuclear receptor subfamily 1 group I member 2, Nuclear receptor subfamily 1 group I member 3, GABA-A receptor alpha-1/beta-2/gamma-2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"fenfluramine","indication_name":"Seizures associated with Dravet syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fintepla","generic_name":"FENFLURAMINE","company_name":"UCB","drug_phase":"marketed","molecular_target":"Alpha-1B adrenergic receptor","drug_class":"fenfluramine","quality_score":10,"revenue":null,"mechanism":"Fintepla works by binding to the Alpha-1B adrenergic receptor, which helps regulate the activity of certain neurons in the brain."},{"drug_id":"fosphenytoin","indication_name":"Epilepsy characterized by intractable complex partial seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cerebyx","generic_name":"FOSPHENYTOIN","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Sodium channel protein type 5 subunit alpha","drug_class":"Anti-epileptic Agent","quality_score":80,"revenue":null,"mechanism":"Cerebyx works by stabilizing the inactivated state of sodium channels, preventing the rapid firing of neurons that can lead to seizures."},{"drug_id":"fosphenytoin","indication_name":"Seizures in Neurosurgery","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cerebyx","generic_name":"FOSPHENYTOIN","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Sodium channel protein type 5 subunit alpha","drug_class":"Anti-epileptic Agent","quality_score":80,"revenue":null,"mechanism":"Cerebyx works by stabilizing the inactivated state of sodium channels, preventing the rapid firing of neurons that can lead to seizures."},{"drug_id":"mephenytoin","indication_name":"Epilepsy characterized by intractable complex partial seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mesantoin","generic_name":"MEPHENYTOIN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Sodium channel alpha subunit","drug_class":"Anti-epileptic Agent","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"neurontin","indication_name":"Partial seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neurontin","generic_name":"Gabapentin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"α2δ subunit of voltage-activated calcium channels","drug_class":"Antiepileptic/Analgesic","quality_score":10,"revenue":null,"mechanism":"Gabapentin binds with high-affinity to α2δ subunit of voltage-activated calcium channels; precise mechanism unknown."},{"drug_id":"neurontin","indication_name":"Seizures associated with amyotrophic lateral sclerosis (ALS)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neurontin","generic_name":"Gabapentin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"α2δ subunit of voltage-activated calcium channels","drug_class":"Antiepileptic/Analgesic","quality_score":10,"revenue":null,"mechanism":"Gabapentin binds with high-affinity to α2δ subunit of voltage-activated calcium channels; precise mechanism unknown."},{"drug_id":"primidone","indication_name":"Epilepsy characterized by intractable complex partial seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mysoline","generic_name":"PRIMIDONE","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily M member 3","drug_class":"Anti-epileptic Agent [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ethotoin","indication_name":"Epilepsy characterized by intractable complex partial seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Peganone","generic_name":"ETHOTOIN","company_name":"Recordati","drug_phase":"marketed","molecular_target":"Sodium channel alpha subunit","drug_class":"Anti-epileptic Agent","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"dilantin","indication_name":"Epilepsy characterized by intractable complex partial seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dilantin","generic_name":"Phenytoin Sodium","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 1 group I member 3","drug_class":"phenytoin","quality_score":80,"revenue":null,"mechanism":"Phenytoin exerts its therapeutic effect by voltage-dependent blockade of membrane sodium channels."},{"drug_id":"dilantin","indication_name":"Prevention of Seizures following Cranial Trauma or Surgery","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dilantin","generic_name":"Phenytoin Sodium","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 1 group I member 3","drug_class":"phenytoin","quality_score":80,"revenue":null,"mechanism":"Phenytoin exerts its therapeutic effect by voltage-dependent blockade of membrane sodium channels."},{"drug_id":"dilantin","indication_name":"Seizures in Neurosurgery","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dilantin","generic_name":"Phenytoin Sodium","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 1 group I member 3","drug_class":"phenytoin","quality_score":80,"revenue":null,"mechanism":"Phenytoin exerts its therapeutic effect by voltage-dependent blockade of membrane sodium channels."},{"drug_id":"topamax","indication_name":"Epilepsy characterized by intractable complex partial seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Topamax","company_name":"Ataturk University","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 1 group I member 2, Carbonic anhydrase 1, Carbonic anhydrase 12","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"fycompa","indication_name":"Secondarily generalized seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fycompa","company_name":"Eisai Inc.","drug_phase":"marketed","molecular_target":"Glutamate receptor ionotropic AMPA","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"divalproex","indication_name":"Epilepsy characterized by intractable complex partial seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Divalproex","company_name":"University of Chicago","drug_phase":"marketed","molecular_target":"Alcohol dehydrogenase [NADP(+)], Histone deacetylase 1, Histone deacetylase 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"carbamazepine","indication_name":"Partial Seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tegretol","generic_name":"carbamazepine","company_name":"Novartis AG (originally Geigy)","drug_phase":"marketed","molecular_target":"Frizzled-8, Nuclear receptor subfamily 1 group I member 2, Neuronal acetylcholine receptor; alpha2/beta4","drug_class":"Mood Stabilizer [EPC]","quality_score":62,"revenue":null,"mechanism":"Carbamazepine reduces polysynaptic responses and blocks post-tetanic potentiation, potentially alleviating seizures and pain."},{"drug_id":"phenacemide","indication_name":"Epilepsy characterized by intractable complex partial seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Phenurone","generic_name":"PHENACEMIDE","company_name":"Abbvie","drug_phase":"marketed","molecular_target":"Sodium channel protein type 1 subunit alpha","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":57,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04426994","title":"Hypomagnesemia Associated With Proton-Pump Inhibitor Use","phase":"","overall_status":"COMPLETED","enrollment_count":211672,"lead_sponsor_name":"Changi General Hospital","has_results":false},{"nct_id":"NCT03944447","title":"Outcomes Mandate National Integration With Cannabis as Medicine","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":200000,"lead_sponsor_name":"OMNI Medical Services, LLC","has_results":false},{"nct_id":"NCT03655223","title":"Early Check: Expanded Screening in Newborns","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30000,"lead_sponsor_name":"RTI International","has_results":false},{"nct_id":"NCT03656939","title":"A Safety Study For Prevenar 13 Among Chinese Children","phase":"","overall_status":"COMPLETED","enrollment_count":21240,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT05140265","title":"De-identified UNMH EEG Corpus Database Creation With Fully De-identified Clinical Information","phase":"","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"University of New Mexico","has_results":false},{"nct_id":"NCT05121324","title":"Pediatric Dose Optimization for Seizures in Emergency Medical Services","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":6700,"lead_sponsor_name":"Stanford University","has_results":false},{"nct_id":"NCT00001192","title":"Neuropsychological Evaluation of Psychiatric and Neurological Patients","phase":"","overall_status":"COMPLETED","enrollment_count":4300,"lead_sponsor_name":"National Institute of Mental Health (NIMH)","has_results":false},{"nct_id":"NCT03059329","title":"Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adult Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures","phase":"","overall_status":"COMPLETED","enrollment_count":3809,"lead_sponsor_name":"Eisai Co., Ltd.","has_results":false},{"nct_id":"NCT06714448","title":"A Study of the Effectiveness of Risk Minimization Measures Related to Depakine® (Sodium Valproate) in Saudi Arabia","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":3500,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT03954314","title":"DEPOSITION - Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":3242,"lead_sponsor_name":"Population Health Research Institute","has_results":false},{"nct_id":"NCT03419260","title":"Electrographic Seizure Management and Neurobehavioral Outcomes in Critically Ill Children","phase":"","overall_status":"RECRUITING","enrollment_count":2500,"lead_sponsor_name":"Children's Hospital of Philadelphia","has_results":false},{"nct_id":"NCT03054285","title":"Does Short-Term Anti-Seizure Prophylaxis After Traumatic Brain Injury Decrease Seizure Rates?","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":2300,"lead_sponsor_name":"Loyola University","has_results":false},{"nct_id":"NCT03822741","title":"Etiology and Treatment of Neonatal Seizure","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Children's Hospital of Fudan University","has_results":false},{"nct_id":"NCT04573803","title":"Pharmacological Management of Seizures Post Traumatic Brain Injury","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":1649,"lead_sponsor_name":"Cambridge University Hospitals NHS Foundation Trust","has_results":false},{"nct_id":"NCT02552511","title":"Epidemiology Study on Neonatal Seizure","phase":"","overall_status":"RECRUITING","enrollment_count":1400,"lead_sponsor_name":"Children's Hospital of Fudan University","has_results":false},{"nct_id":"NCT07072624","title":"Early Post-Traumatic Seizures Prevention Trial (E-PTS Trial)","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":1260,"lead_sponsor_name":"All India Institute of Medical Sciences, Jodhpur","has_results":false},{"nct_id":"NCT03478852","title":"Investigating Epilepsy: Screening and Evaluation","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"National Institute of Neurological Disorders and Stroke (NINDS)","has_results":false},{"nct_id":"NCT01618695","title":"A Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset Seizures","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":940,"lead_sponsor_name":"Eisai Co., Ltd.","has_results":true},{"nct_id":"NCT03529045","title":"Registry of Subjects With Drug Resistant Epilepsy and Treated With the VNS Therapy System.","phase":"","overall_status":"COMPLETED","enrollment_count":827,"lead_sponsor_name":"LivaNova","has_results":false},{"nct_id":"NCT04022486","title":"Seizures in Infants Hospitalized in Pediatric Intensive Care Unit for Bronchiolitis","phase":"","overall_status":"COMPLETED","enrollment_count":805,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT05267405","title":"Mainz Epilepsy Registry","phase":"","overall_status":"UNKNOWN","enrollment_count":700,"lead_sponsor_name":"Johannes Gutenberg University Mainz","has_results":false},{"nct_id":"NCT06444126","title":"The Incidence And Risk Factors Of Recurrent Febrile Seizures And Epilepsy Following Febrile Seizures","phase":"","overall_status":"RECRUITING","enrollment_count":650,"lead_sponsor_name":"Pham Ngoc Thach University of Medicine","has_results":false},{"nct_id":"NCT03722212","title":"Early Diagnosis of the GLUT1 Deficiency Syndrome With a Blood Based Test","phase":"NA","overall_status":"COMPLETED","enrollment_count":636,"lead_sponsor_name":"METAFORA biosystems","has_results":false},{"nct_id":"NCT01463306","title":"A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":605,"lead_sponsor_name":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","has_results":true},{"nct_id":"NCT06442748","title":"Short Versus Long-term Levetiracetam in Brain Tumors","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":604,"lead_sponsor_name":"Tata Memorial Centre","has_results":false},{"nct_id":"NCT06922734","title":"Epilepsy Watch After Vascular Events: Frequency, Outcomes, and Risk Markers","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":602,"lead_sponsor_name":"University Medical Centre Maribor","has_results":false},{"nct_id":"NCT03561168","title":"Review of Diagnostic Yield of MRI Brain Results in Children Under Age 3 Years","phase":"","overall_status":"COMPLETED","enrollment_count":561,"lead_sponsor_name":"Baylor College of Medicine","has_results":false},{"nct_id":"NCT00298246","title":"Clinical and Immunological Investigations of Subtypes of Autism","phase":"","overall_status":"COMPLETED","enrollment_count":557,"lead_sponsor_name":"National Institute of Mental Health (NIMH)","has_results":false},{"nct_id":"NCT04141891","title":"Advancing Understanding of Transportation Options","phase":"NA","overall_status":"COMPLETED","enrollment_count":529,"lead_sponsor_name":"University of Colorado, Denver","has_results":true},{"nct_id":"NCT03059381","title":"Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adolescence Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures","phase":"","overall_status":"COMPLETED","enrollment_count":519,"lead_sponsor_name":"Eisai Co., Ltd.","has_results":false},{"nct_id":"NCT05422664","title":"Acute Sympotomatic Seizure Secondary to Autoimmune Encephalitis and Autoimmune-associated Epilepsy","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Liu Yonghong","has_results":false},{"nct_id":"NCT01832038","title":"Study to Evaluate the Safety, Tolerability, and Efficacy of Long-term Adjunctive Therapy With Lacosamide in Adults With Partial-onset Seizures","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":473,"lead_sponsor_name":"UCB Pharma SA","has_results":true},{"nct_id":"NCT03083665","title":"A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":449,"lead_sponsor_name":"UCB Biopharma SRL","has_results":true},{"nct_id":"NCT03373383","title":"Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":411,"lead_sponsor_name":"UCB Biopharma S.P.R.L.","has_results":true},{"nct_id":"NCT03370120","title":"Study to Test the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":406,"lead_sponsor_name":"UCB Biopharma SRL","has_results":true},{"nct_id":"NCT00699972","title":"Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":390,"lead_sponsor_name":"Eisai Inc.","has_results":true},{"nct_id":"NCT05614063","title":"A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":380,"lead_sponsor_name":"Xenon Pharmaceuticals Inc.","has_results":false},{"nct_id":"NCT01713946","title":"A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":366,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT04879147","title":"Observational and Diagnostical Study on Transient Allostatic Responses of Thyroid Function After Syncopation and Seizure","phase":"","overall_status":"UNKNOWN","enrollment_count":350,"lead_sponsor_name":"Ruhr University of Bochum","has_results":false},{"nct_id":"NCT06038617","title":"Safety of Simultaneous mRNA COVID-19 Vaccine With Other Childhood Vaccines in Young Children","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":344,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT01262677","title":"Once-A-Day Pregabalin For Partial Seizures","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":325,"lead_sponsor_name":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","has_results":true},{"nct_id":"NCT05076617","title":"A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures","phase":"PHASE3","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":300,"lead_sponsor_name":"UCB Biopharma SRL","has_results":false},{"nct_id":"NCT01389596","title":"A Study of the Efficacy and Safety of Pregabalin as Add-On Therapy for Partial Onset Seizures in Children Ages 4-16 Years","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":295,"lead_sponsor_name":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","has_results":true},{"nct_id":"NCT00448539","title":"Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":286,"lead_sponsor_name":"Eisai Inc.","has_results":true},{"nct_id":"NCT02881957","title":"Hypovitaminosis D in Neurocritical Patients","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":274,"lead_sponsor_name":"University of Utah","has_results":true},{"nct_id":"NCT02431780","title":"A Multicentre Clinical Investigation of a Decision Support Algorithm for Neonatal Seizure Detection","phase":"NA","overall_status":"COMPLETED","enrollment_count":264,"lead_sponsor_name":"University College Cork","has_results":false},{"nct_id":"NCT07401433","title":"Levetiracetam Versus Phenobarbitone for the Treatment of Neonatal Seizures in a Tertiary Care Hospital.","phase":"NA","overall_status":"COMPLETED","enrollment_count":260,"lead_sponsor_name":"Hayat Abad Medical Complex, Peshawar","has_results":false},{"nct_id":"NCT03399318","title":"Aggressive Antipyretics for Fever Reduction in CNS Malaria","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":256,"lead_sponsor_name":"University of Rochester","has_results":true},{"nct_id":"NCT02477839","title":"Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects ≥1 Month to <4 Years With Partial-onset Seizures","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":255,"lead_sponsor_name":"UCB BIOSCIENCES, Inc.","has_results":true},{"nct_id":"NCT04257604","title":"A Study of Perampanel as Add-on Therapy in Adult and Adolescent Participants With Focal Seizures","phase":"","overall_status":"COMPLETED","enrollment_count":243,"lead_sponsor_name":"Eisai Limited","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}